Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer

NCT ID: NCT00003267

Last Updated: 2012-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

214 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: The use of pelvic drains may help to prevent complications following radical hysterectomy and pelvic lymphadenectomy. It is not known whether receiving pelvic drains during surgery is more effective than receiving no pelvic drains during surgery in patients with uterine, cervical, or vaginal cancer.

PURPOSE: Randomized phase III trial to determine if the use of pelvic drains following radical hysterectomy and pelvic lymphadenectomy is effective in treating patients with uterine, cervical, or vaginal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES: I. Evaluate postoperative complications associated with the use or omission of pelvic drains following radical hysterectomy and node dissection that includes suturing of the vaginal cuff and no peritonealization.

OUTLINE: This is a randomized, two-arm study. All patients receive radical hysterectomy (Rutledge-Piver II-III type) and pelvic lymphadenectomy, without pelvic and parietal peritonealization, with suturing of the vaginal cuff and closure of fascia and cutaneous layers; lumboaortic node dissection is optional. Patients are randomized during surgery to one of two arms: those on arm I receive pelvic drains and those on arm II do not. Those in arm I have drains applied in the pelvis, and lymph is collected by vaginal and/or transabdominal drains located in both retroperitoneal fossa. Drains are removed when the loss is less than 50 mL in 24 hours. Patients in both arms are followed at 2-3 months and 12 months after surgery.

PROJECTED ACCRUAL: 214 patients will be accrued for this study within 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Endometrial Cancer Infection Perioperative/Postoperative Complications Vaginal Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stage I cervical cancer stage II cervical cancer stage I vaginal cancer stage II vaginal cancer stage I endometrial carcinoma stage II endometrial carcinoma infection perioperative/postoperative complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

SUPPORTIVE_CARE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

infection prophylaxis and management

Intervention Type PROCEDURE

management of therapy complications

Intervention Type PROCEDURE

surgical procedure

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior neoadjuvant chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sergio L. Pecorelli, MD

Role: STUDY_CHAIR

Spedali Civili di Brescia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaiser Franz Josef Hospital

Vienna (Wien), , Austria

Site Status

Universitair Ziekenhuis Antwerpen

Edegem, , Belgium

Site Status

U.Z. Gasthuisberg

Leuven, , Belgium

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

University Medical Center

Freiburg im Breisgau, , Germany

Site Status

Universita di Brescia

Brescia, , Italy

Site Status

Instituto Scientifico H.S. Raffaele

Milano (Milan), , Italy

Site Status

Istituto Nazionale per lo Studio e la Cura dei Tumori

Milano (Milan), , Italy

Site Status

Azienda Ospedaliera Di Parma

Parma, , Italy

Site Status

University and I.R.C.C.S. Policlinico San Matteo

Pavia, , Italy

Site Status

Ospedale di Circolo e Fondazione Macchi

Varese, , Italy

Site Status

Ospedale Civile

Voghera (PV), , Italy

Site Status

Antoni van Leeuwenhoekhuis

Amsterdam, , Netherlands

Site Status

Medisch Spectrum Twente

Enschede, , Netherlands

Site Status

Leiden University Medical Center

Leiden, , Netherlands

Site Status

Academisch Ziekenhuis Utrecht

Utrecht, , Netherlands

Site Status

Hospitais da Universidade de Coimbra (HUC)

Coimbra, , Portugal

Site Status

Instituto Valenciano De Oncologia

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium France Germany Italy Netherlands Portugal Spain

References

Explore related publications, articles, or registry entries linked to this study.

Franchi M, Trimbos JB, Zanaboni F, v d Velden J, Reed N, Coens C, Teodorovic I, Vergote I. Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patients. Eur J Cancer. 2007 May;43(8):1265-8. doi: 10.1016/j.ejca.2007.03.011. Epub 2007 Apr 26.

Reference Type RESULT
PMID: 17466514 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EORTC-55962

Identifier Type: -

Identifier Source: secondary_id

EORTC-55962

Identifier Type: -

Identifier Source: org_study_id